New publication : Development and characterization of NILK-2301

A novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers

Anja Seckinger^1†, Sara Majocchi^2†, Valéry Moine², Lise Nouveau ², Hoang Ngoc³, Bruno Daubeuf2, Ulla Ravn², Nicolas Pleche², Sebastien Calloud², Lucile Broyer², Laura Cons², Adeline Lesnier², Laurence Chatel², Anne Papaioannou², Susana Salgado‑Pires², Sebastian Krämer4, Ines Gockel⁴, Florian Lordick⁵, Krzysztof Masternak², Yves Poitevin², Giovanni Magistrelli², Pauline Malinge², Limin Shang², Sonja Kallendrusch^3,6, Klaus Strein¹ and Dirk Hose^1*

Light Chain Bioscience and partner LamKap Bio are proud to publish the preclinical findings on the CEACAM5xCD3 T cell engager, NILK-2301, Co-authored by A. Seckinger, S. Majocchi, the manuscript describes the development of the bispecific antibody generated on LCB’s proprietary Kappa-Lambda Body platform, to support the immunotherapy approach for the treatment of CEACAM5-expressing cancers. LCB will Sponsor the clinical development of NILK-2301 with expected entry into patients early 2024.

Read: Full article

Published: 12 December 2023│volume 16, Article number: 117 (2023)

Back to News